Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled ...

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

As af Klint’s fame has grown, so have the questions—about what she believed, whom she worked with, and who should be allowed ...

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

Moderna's John Ward argues that the future of in-house trademark practice will belong to the teams that have the courage to ...